Health insurance

Survey: Approximately 10% of US Employers May Drop GLP-1 Coverage in 2027

Are GLP-1 drugs breaking employer budgets or are the long-term savings worth the upfront cost?

Published JUN 12

Survey: Approximately 10% of US Employers May Drop GLP-1 Coverage in 2027

story

Above: Charles Barkley advertising GLP-1 medication at Penn Station in New York City, May 31. Image credit: Erica Denhoff/Icon Sportswire/Getty Images

The Spin

Narrative A

GLP-1 drugs are blowing up employer health care budgets, and no amount of step therapy or utilization management is fixing it. Nearly 80% of employers say these medications are driving cost increases, and the pricing system is rigged against plan sponsors who can see cheaper cash-pay rates on consumer platforms but can't access them. Cutting or restructuring coverage is a rational response to a broken system that keeps getting more expensive and seems to satisfy no one anyway.

Pharmaceutical Commerce Pharmaceutical Commerce

Narrative B

Dropping GLP-1 coverage is a decision to pay more later. Obesity drives over 250 conditions and costs the U.S. more than $261 billion annually, meaning employers who skip coverage are just deferring and compounding those costs. A healthier workforce means less absenteeism, stronger retention and a benefits package that actually attracts talent, especially younger workers who rank health coverage above higher pay.

Newsweek on X Newsweek